Search

  5. ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

    Press release

    … ProQR Receives Fast Track Designation from FDA for QR-421a … & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to begin enrollment in …

  6. ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

    Press release

    … ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of … in Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the … Aniz Girach, Ophthalmologist and Chief Medical Officer of ProQR. “With the ongoing trials in LCA10 and Ushers syndrome …

  8. On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

    Press release

    … On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day LEIDEN, the Netherlands, Feb. … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Together with our partners at the Leiden Bio Science … Sariette Witte Investor Relations T: +1 213 261 8891 ir@proqr.com …